WBAG:PFE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide.


Snowflake Analysis

Outstanding track record established dividend payer.


Similar Companies

Share Price & News

How has Pfizer's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PFE has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

5.2%

PFE

0.8%

AT Pharmaceuticals

3.2%

AT Market


1 Year Return

-21.4%

PFE

12.9%

AT Pharmaceuticals

-19.4%

AT Market

Return vs Industry: PFE underperformed the Austrian Pharmaceuticals industry which returned 14.4% over the past year.

Return vs Market: PFE underperformed the Austrian Market which returned -19.3% over the past year.


Shareholder returns

PFEIndustryMarket
7 Day5.2%0.8%3.2%
30 Day-5.0%0.9%-5.1%
90 Day-1.9%9.5%7.3%
1 Year-18.3%-21.4%16.6%12.9%-18.5%-19.4%
3 Year17.7%5.4%32.3%16.9%-12.9%-19.5%
5 Yearn/a25.5%3.8%16.8%2.2%

Price Volatility Vs. Market

How volatile is Pfizer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Pfizer undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PFE (€30.6) is trading below our estimate of fair value (€73.12)

Significantly Below Fair Value: PFE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PFE is good value based on its PE Ratio (12x) compared to the Pharmaceuticals industry average (24.7x).

PE vs Market: PFE is poor value based on its PE Ratio (12x) compared to the Austrian market (11.2x).


Price to Earnings Growth Ratio

PEG Ratio: PFE is poor value based on its PEG Ratio (3.2x)


Price to Book Ratio

PB vs Industry: PFE is good value based on its PB Ratio (2.9x) compared to the XE Pharmaceuticals industry average (3.2x).


Next Steps

Future Growth

How is Pfizer forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

3.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PFE's forecast earnings growth (3.7% per year) is above the savings rate (0.5%).

Earnings vs Market: PFE's earnings (3.7% per year) are forecast to grow slower than the Austrian market (21.6% per year).

High Growth Earnings: PFE's earnings are forecast to grow, but not significantly.

Revenue vs Market: PFE's revenue (3.1% per year) is forecast to grow slower than the Austrian market (3.3% per year).

High Growth Revenue: PFE's revenue (3.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PFE's Return on Equity is forecast to be high in 3 years time (24.4%)


Next Steps

Past Performance

How has Pfizer performed over the past 5 years?

18.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PFE has high quality earnings.

Growing Profit Margin: PFE's current net profit margins (31.2%) are higher than last year (21.3%).


Past Earnings Growth Analysis

Earnings Trend: PFE's earnings have grown by 18.3% per year over the past 5 years.

Accelerating Growth: PFE's earnings growth over the past year (37.7%) exceeds its 5-year average (18.3% per year).

Earnings vs Industry: PFE earnings growth over the past year (37.7%) exceeded the Pharmaceuticals industry 7%.


Return on Equity

High ROE: PFE's Return on Equity (24.2%) is considered high.


Next Steps

Financial Health

How is Pfizer's financial position?


Financial Position Analysis

Short Term Liabilities: PFE's short term assets ($34.7B) exceed its short term liabilities ($33.9B).

Long Term Liabilities: PFE's short term assets ($34.7B) do not cover its long term liabilities ($67.1B).


Debt to Equity History and Analysis

Debt Level: PFE's debt to equity ratio (78%) is considered high.

Reducing Debt: PFE's debt to equity ratio has increased from 53.3% to 78% over the past 5 years.

Debt Coverage: PFE's debt is well covered by operating cash flow (27.5%).

Interest Coverage: PFE's interest payments on its debt are well covered by EBIT (12.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Pfizer current dividend yield, its reliability and sustainability?

4.47%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: PFE's dividend (4.47%) is higher than the bottom 25% of dividend payers in the Austrian market (1.65%).

High Dividend: PFE's dividend (4.47%) is low compared to the top 25% of dividend payers in the Austrian market (4.94%).


Stability and Growth of Payments

Stable Dividend: PFE's dividends per share have been stable in the past 10 years.

Growing Dividend: PFE's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (51.3%), PFE's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: PFE's dividends in 3 years are forecast to be covered by earnings (53.8% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average management tenure


CEO

Albert Bourla (58yo)

1.5yrs

Tenure

US$17,928,963

Compensation

Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and has been its Executive Director since February 23, 2018. Dr. Bourla was Chief Operating Officer  ...


CEO Compensation Analysis

Compensation vs Market: Albert's total compensation ($USD17.93M) is above average for companies of similar size in the Austrian market ($USD4.02M).

Compensation vs Earnings: Albert's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Albert Bourla
Chairman of the Board & CEO1.5yrsUS$17.93m0.0038% $6.5m
John Young
Group President & Chief Business Officer8.08yrsUS$8.96m0.0076% $13.0m
Frank D'Amelio
CFO & EVP of Global Supply & Business Operations12.83yrsUS$11.08m0.0077% $13.0m
Mikael Dolsten
Chief Scientific Officer and President of Worldwide Research1.5yrsUS$9.60mno data
Jennifer Damico
Senior VP0.33yrno data0.00014% $237.6k
Lidia Fonseca
Executive VP and Chief Digital & Technology Officer1.5yrsno data0.00078% $1.3m
Charles Triano
Senior Vice President of Investor Relations12.08yrsno datano data
Douglas Lankler
Executive VP & General Counsel6.58yrsno data0.0014% $2.4m
Rady Johnson
Executive VP and Chief Compliance6.58yrsno data0.0013% $2.1m
Alexander MacKenzie
Executive VP & Chief Development Officer4.33yrsno data0.0022% $3.7m

5.5yrs

Average Tenure

58yo

Average Age

Experienced Management: PFE's management team is seasoned and experienced (5.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Albert Bourla
Chairman of the Board & CEO1.5yrsUS$17.93m0.0038% $6.5m
W. Cornwell
Independent Director23.42yrsUS$385.00kno data
Shantanu Narayen
Lead Independent Director2.25yrsUS$400.00kno data
Ronald Blaylock
Independent Director3.42yrsUS$350.00kno data
James Kilts
Independent Director12.83yrsUS$355.00k0.000040% $67.9k
Suzanne Nora Johnson
Independent Director12.83yrsUS$380.00k0.00018% $305.4k
James Smith
Independent Director6.08yrsUS$380.00k0.000060% $101.8k
Charles Hagel
Member of Emerging Markets Advisory Boardno datano datano data
Joseph Echevarria
Independent Director5.08yrsUS$365.00kno data
Helen Hobbs
Independent Director8.58yrsUS$383.60kno data

6.1yrs

Average Tenure

63yo

Average Age

Experienced Board: PFE's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PFE insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Pfizer Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pfizer Inc.
  • Ticker: PFE
  • Exchange: WBAG
  • Founded: 1849
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$191.697b
  • Listing Market Cap: US$169.690b
  • Shares outstanding: 5.55b
  • Website: https://www.pfizer.com

Number of Employees


Location

  • Pfizer Inc.
  • 235 East 42nd Street
  • New York
  • New York
  • 10017
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PFENYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1968
PFE *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1968
0Q1NLSE (London Stock Exchange)YesCommon StockGBUSDJan 1968
PFEOM (OMX Nordic Exchange Stockholm)YesCommon StockSESEKJan 1968
PFEDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1968
PFEXTRA (XETRA Trading Platform)YesCommon StockDEEURJan 1968
PFEBVC (Bolsa de Valores de Colombia)YesCommon StockCOCOPJan 1968
PFESBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBSEKJan 1968
PFESNSE (Santiago Stock Exchange)YesCommon StockCLUSDJan 1968
PF-UETLX (Eurotlx)YesCommon StockITEURJan 1968
PFEWBAG (Wiener Boerse AG)YesCommon StockATEURJan 1968
PFEBVL (Bolsa de Valores de Lima)YesCommon StockPEUSDJan 1968
US_PFE_KAS (Kazakhstan Stock Exchange)YesCommon StockKZKZTJan 1968
PFEBASE (Buenos Aires Stock Exchange)CEDEAR EACH 2 REP 1 ORD USD0.05ARARSSep 2000
PFIZ34BOVESPA (Bolsa de Valores de Sao Paulo)BDR REPR 1 COM STK NPVBRBRLMay 2011

Biography

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and research collaboration and license agreement with BioInvent International AB. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/07 21:15
End of Day Share Price2020/07/07 00:00
Earnings2020/03/29
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.